AVITA Medical, Inc. (RCEL) News
Filter RCEL News Items
RCEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RCEL News From Around the Web
Below are the latest news stories about AVITA MEDICAL INC that investors may wish to consider to help them evaluate RCEL as an investment opportunity.
AVITA Medical to Host Investor Webinar BriefingVALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on December 5, 2023, at 2:00 p.m. (PS |
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare ConferenceVALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time. A live webcast of the present |
AVITA Medical Updates Full Year 2023 GuidanceVALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced an update to its full year 2023 guidance. This update is a result of slower-than-anticipated progression through the customer’s Value Analysis Committee (VAC) processes, driven by the expanded label application |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching for Friday morning! |
AVITA Medical, Inc. (NASDAQ:RCEL) Q3 2023 Earnings Call TranscriptAVITA Medical, Inc. (NASDAQ:RCEL) Q3 2023 Earnings Call Transcript November 9, 2023 AVITA Medical, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.53. Operator: Good day, and thank you for standing by. Welcome to the AVITA Medical Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. After […] |
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior YearVALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter September 30, 2023. Financial Highlights and Recent Updates Commercial revenue of $13.5 million, an approximately 51% increase compared to $9.0 million for the same period |
AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to EuropeVALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered into a distribution agreement with PolyMedics Innovations GmbH, to strategically expand its global presence to Europe. Under the terms of the agreement, PolyMedics Innovations will serve as the C |
AVITA Medical, Inc.'s (NASDAQ:RCEL) 32% Dip In Price Shows Sentiment Is Matching RevenuesUnfortunately for some shareholders, the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has dived 32% in the last... |
AVITA Medical to Announce Third Quarter 2023 Financial ResultsVALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its third quarter 2023 financial results after the close of the U.S. financial markets on Thursday, November 9, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time |
AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth InitiativesPreliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed$40 million funded at close; $50 million of additional non-dilutive capital available at the Company’s option, based on the achievement of certain revenue thresholdsCapital from the transaction will support execution of strategic expansion and fuel continued growth VALENCIA, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerat |